CVE-2015-3965
highpriority · track · 36EPSS 0.029 · 87 %ileEUUSEPSS · scored 2026-10-27
Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.
remediations
Vendor fix, mitigation, or workaround guidance, as published by each source.
No vendor fix yet; a mitigation is available.
- MitigationSymbiq Infusion Systemcisa_csaf_ot
Hospira has provided compensating measures to help mitigate risks associated with this vulnerability. As previously announced by Hospira in 2013, the Symbiq Infusion System would be retired on May 31, 2015, and will be fully removed from the market by December 2015.
cvss
Technical severity, 0–10. One row per scoring source.
base score 0–10 · higher = more severe · hover a vector to decode
weaknesses
The CWE weakness classes this flaw belongs to.
affected products (4)
Products and version ranges known to be affected.
- pfizer symbiq infusion system firmware≤ 3.13nvdUScpe:2.3:o:pfizer:symbiq_infusion_system_firmware:*:*:*:*:*:*:*:*
advisories (1)
Vendor and ecosystem advisories describing this.
- ICSA-15-174-01Hospira Symbiq Infusion System Vulnerability2015-03-26icsa · cisa_csaf_otUS
This CSAF advisory was extracted from unstructured data and may contain inaccuracies. If you notice any errors, please reach out to the designated contact at CISA CSAF: central@cisa.dhs.gov
also known as (3)
Other names and identifiers for this entity.
sources
Which sources assert this record, and when.
references (4)
External citations — patches, advisories, analysis.
Attackers weaponise vulnerabilities like this against internet-exposed services. See what is exposed on your perimeter with a free passive scan.
Free scan